News Releases

FOSTER CITY, Calif., Nov. 3, 2015 /PRNewswire/ -- SciClone Pharmaceuticals, Inc. (NASDAQ: SCLN) today announced that Friedhelm Blobel, PhD, Chief Executive Officer, will participate in a panel discussion at the Boston Biotech Conferences (BBC) NY/NJ CEO conference on November 12^th, at the Apella in New York City.

The conference will focus on the 2016 healthcare industry outlook, disruptive innovation and venture philanthropy, non-dilutive financing, pricing and reimbursement, defining the value of drugs, innovation in drug discovery, personalized medicine, creative financing, emerging markets, innovative deal structures, and more. Dr. Blobel will participate in a panel titled, "Importance of Emerging Markets."

The Boston Biotech Conferences (BBC)'s mission is to build a vibrant community of biopharma leaders, which will help to drive biopharma innovation in biotech, by convening leaders across industry and academia. The conferences are exclusive, thought-leader forums for senior biopharma executives. Each conference is highly interactive and co-hosted by healthcare industry leaders to foster discussions and facilitate information-sharing, networking, and corporate development within the biopharma community. For more information, visit: http://bbbiotechconference.com/conference-details.php?id=34

About SciClone

SciClone Pharmaceuticals is a revenue-generating, specialty pharmaceutical company with a substantial commercial business in China and a product portfolio spanning major therapeutic markets including oncology, infectious diseases and cardiovascular disorders. SciClone's proprietary lead product, ZADAXIN^® (thymalfasin), is approved in over 30 countries and may be used for the treatment of hepatitis B (HBV), hepatitis C (HCV), and certain cancers, and as a vaccine adjuvant, according to the local regulatory approvals. The Company has successfully in-licensed and commercialized products with the potential to become future market leaders and to drive the Company's long-term growth, including DC Bead®, a novel treatment for liver cancer. Through its promotion business with pharmaceutical partners, SciClone also markets multiple branded products in China which are therapeutically differentiated. SciClone is a publicly-held corporation based in Foster City, California, and trades on the NASDAQ Global Select Market under the symbol SCLN. For additional information, please visit www.sciclone.com.

Forward-Looking Statements

This press release contains forward-looking statements regarding expected financial results and expectations. Readers are urged to consider statements that include the words "may," "will," "would," "could," "should," "might," "believes," "estimates," "projects," "potential," "expects," "plans," "anticipates," "intends," "continues," "forecast," "designed," "goal," "unaudited," "approximately" or the negative of those words or other comparable words to be uncertain and forward-looking. These statements are subject to risks and uncertainties that are difficult to predict and actual outcomes may differ materially.  Please also refer to other risks and uncertainties described in SciClone's filings with the SEC. All forward-looking statements are based on information currently available to SciClone and SciClone assumes no obligation to update any such forward-looking statements.

SciClone, SciClone Pharmaceuticals, the SciClone Pharmaceuticals design, the SciClone logo and ZADAXIN are registered trademarks of SciClone Pharmaceuticals, Inc. in the United States and numerous other countries.

Logo - http://photos.prnewswire.com/prnh/20150722/240358LOGO

SOURCE SciClone Pharmaceuticals, Inc.